Search jobs 08-Apr-2021 Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
-Preliminary data from 103 patients in the expansion portion of a Phase 1b clinical trial demonstrated the drug was well tolerated and anti-tumor activity was noted
- Unique opportunity to leverage CELsignia platform to advance development of a first-in-class targeted therapy
-
Management to host conference call/webcast today, April 8, 2021, at 5:00 p.m. ET
MINNEAPOLIS (BUSINESS WIRE) #cancer Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced it has entered into a global licensing agreement with Pfizer Inc. (NYSE:PFE) granting Celcuity exclusive rights to Pfizer’s gedatolisib, a Phase 1b pan-PI3K/mTOR inhibitor. Ge
Cazoo to Become Listed on NYSE through $7 0 Billion Business Combination with AJAX I
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
STRATA Skin Sciences Reports Fourth Quarter and Full Year 2020 Financial Results
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Share this article
YEHUD, Israel, March 11, 2021 /PRNewswire/
Magal Security Systems, Ltd. (Nasdaq: MAGS), a leading international provider of comprehensive physical, video, and access control security products and solutions, as well as critical site management, will report financial results for its 2020 fourth quarter and year ended December 31, 2020 on Tuesday, April 6, 2021. Management will conduct a conference call to review the Company s financial results at 10:00 a.m. Eastern Time the same day.
Earnings Conference Call Information:
To participate, please use one of the following teleconferencing numbers. The Company requests that participants dial in 10 minutes before the conference call commences and use the conference ID number 13714719.